Pradaxa
Atrial Fibrillation, Venous Thromboembolism
150mg
intended to alleviate the risk of stroke and systemic embolism in atrial fibrillation.
Dabigatran is the medicine ingredient covered on this page. The catalog summary describes it as follows: Inhibits thrombin activity to prevent blood clot formation in patients at risk of stroke or embolism. The products below may vary by brand, strength, form, release profile, or combination ingredients, so use the listing as a checkpoint before comparing it with a prescription or product label.
Atrial Fibrillation, Venous Thromboembolism
150mg
intended to alleviate the risk of stroke and systemic embolism in atrial fibrillation.
Blood-thinning medicines are useful because they reduce clot risk, but that same effect makes bleeding checks central.
For Dabigatran, the starting fact is its catalog description: Inhibits thrombin activity to prevent blood clot formation in patients at risk of stroke or embolism. That sentence tells you what to verify next - the diagnosis, the product form, and the instructions that come with the exact listing.
Black stools, vomiting blood, coughing blood, severe headache, unexplained bruising, major falls, or uncontrolled bleeding need urgent advice.
Do not stop anticoagulants or antiplatelets abruptly unless a clinician gives a clear plan.
Tell a healthcare professional about current medicines, supplements, allergies, pregnancy or breastfeeding, kidney or liver disease, and any previous reaction to this ingredient or its drug class.
This page provides an educational overview of Dabigatran and does not replace medical advice, diagnosis, product labelling, or prescribing instructions. Individual products can differ in active ingredient combinations, strength, formulation, storage, route, and monitoring requirements. Do not start, stop, switch, or combine medicines based only on this catalog page; use the specific product label and guidance from a qualified healthcare professional.